Artem Tcherkassov

This inventor holds 7 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent. Top assignees: The University of British Columbia, Simon Fraser University. Active years: 2009-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Artem Tcherkassov. Retrieved from https://idiyas.com/inventor/artem-tcherkassov

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 4)

% Patents Active = 57.1

CIPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.1

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

7 out of 962

The University of British Columbia

patents

2 out of 157

Simon Fraser University

patents

where one patent can have more than one assignee

Years Active: 2009-2024

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12017975 - Myc-Max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith (2024-06-25),

2. 10633338 - Binding Function 3 (BF3) site compounds as therapeutics and methods for their use (2020-04-28),

3. 10351527 - [object Object] (2019-07-16),

4. 10011573 - Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use (2018-07-03),

5. 8105789 - Diagnosis and treatment of infectious diseases through indel-differentiated proteins (2012-01-31),

6. 8032347 - Methods and apparatus for protein sequence analysis (2011-10-04),

7. 7572589 - Diagnosis and treatment of infectious diseases through indel-differentiated proteins (2009-08-11),

Title: The Innovative Contributions of Artem Tcherkassov

Introduction

Artem Tcherkassov is a prominent inventor based in Vancouver, Canada. He has made significant contributions to the field of cancer therapeutics, holding a total of 7 patents. His work focuses on developing innovative compounds that target specific cancer pathways, providing new avenues for treatment.

Latest Patents

Among his latest patents is the "Myc-Max inhibitor compound therapeutics for cancer treatment." This invention presents Myc-Max inhibitory compounds designed to treat various types of cancer, including prostate cancer, breast cancer, colon cancer, and more. Another notable patent is for "Binding Function 3 (BF3) site compounds as therapeutics and methods for their use," which outlines the use of specific compounds for treating prostate cancer and other indications.

Career Highlights

Artem Tcherkassov has worked at esteemed institutions such as the University of British Columbia and Simon Fraser University. His research has significantly advanced the understanding of cancer treatment methodologies, making him a key figure in the field.

Collaborations

Throughout his career, Tcherkassov has collaborated with notable colleagues, including Paul Rennie and Neil E. Reiner. These partnerships have fostered a collaborative environment that enhances research and innovation in cancer therapeutics.

Conclusion

Artem Tcherkassov's contributions to cancer treatment through his innovative patents and collaborations highlight his importance in the field of medical research. His work continues to pave the way for new therapeutic options for patients battling cancer.

Profile summary based on public USPTO records.